JRSS: AI 评分 35/100 — AI 分析 (4月 2026)

JRSIS Health Care Corporation operates Jiarun Hospital in Harbin, China, providing a range of medical services. The company focuses on various medical areas, including pediatrics, dermatology, traditional Chinese medicine, and general surgery, serving the Heilongjiang Province.

Key Facts: AI Score: 35/100 Sector: Healthcare

公司概况

概要：

JRSIS Health Care Corporation, based in Harbin, China, operates Jiarun Hospital, offering diverse medical services such as pediatrics, dermatology, and traditional Chinese medicine. With 950 beds, the hospital serves the Heilongjiang Province. The company faces challenges with negative profitability and operates in a competitive healthcare market.

JRSS是做什么的？

Founded in 2006, JRSIS Health Care Corporation, formerly known as China Runteng Medical Group Co., Ltd, is a healthcare provider operating in Harbin, Heilongjiang Province, China. The company's primary asset is Jiarun Hospital, a 950-bed facility offering a broad spectrum of medical services. These services encompass pediatrics, dermatology, ears, nose, throat, traditional Chinese medicine, ophthalmology, internal medicine, dentistry, general surgery, rehabilitation science, gynecology, and general medical services. JRSIS Health Care Corporation aims to provide comprehensive healthcare solutions to the local population. The hospital is equipped to handle a wide range of medical needs, from routine check-ups to specialized treatments. The company changed its name in November 2013, reflecting its commitment to the healthcare sector. The company's operations are concentrated within the Heilongjiang Province, making it a regional player in the Chinese healthcare market. JRSIS Health Care Corporation faces challenges related to profitability, as indicated by its negative profit margin.

JRSS的投资论点是什么？

Investing in JRSIS Health Care Corporation presents a high-risk, high-reward scenario. The company operates in the growing Chinese healthcare market but faces significant challenges. Key value drivers include potential expansion of services and increased patient volume at Jiarun Hospital. However, the company's negative profit margin of -47.0% raises concerns about its financial sustainability. Growth catalysts include potential government healthcare reforms and increased demand for medical services in the Heilongjiang Province. The company's ability to improve operational efficiency and reduce costs is crucial for achieving profitability. Potential investors should carefully consider the risks associated with investing in an OTC-listed company with limited financial information and negative earnings. The company's beta of -0.63 suggests a low correlation with the overall market.

JRSS在哪个行业运营？

JRSIS Health Care Corporation operates within the Chinese healthcare market, which is experiencing significant growth due to an aging population and increasing healthcare awareness. The market is competitive, with both public and private hospitals vying for patients. Key trends include the increasing adoption of telemedicine and the growing demand for specialized medical services. JRSIS Health Care Corporation's position within this market is challenged by its negative profitability and limited geographic reach. Competitors include other healthcare providers in the Heilongjiang Province and national hospital chains.

Medical - Care Facilities

Healthcare

JRSS有哪些增长机遇？

Expansion of Medical Services: JRSIS Health Care Corporation can expand its range of medical services to attract more patients and increase revenue. This could involve adding new specialties, such as cardiology or oncology, or investing in advanced medical equipment. The market for specialized medical services in China is growing rapidly, driven by increasing healthcare awareness and rising incomes. Timeline: 2-3 years. Market Size: The Chinese healthcare market is projected to reach $2.3 trillion by 2030.
Increased Patient Volume: JRSIS Health Care Corporation can increase patient volume at Jiarun Hospital by improving its marketing and outreach efforts. This could involve advertising in local media, partnering with local businesses, and offering discounts and promotions. The demand for medical services in the Heilongjiang Province is growing due to an aging population and increasing urbanization. Timeline: Ongoing. Market Size: The number of hospital visits in China is projected to increase by 5% annually over the next decade.
Strategic Partnerships: JRSIS Health Care Corporation can form strategic partnerships with other healthcare providers, such as hospitals, clinics, and pharmaceutical companies. This could involve sharing resources, co-marketing services, and developing new products and services. Strategic partnerships can help JRSIS Health Care Corporation expand its reach, improve its efficiency, and enhance its competitiveness. Timeline: 1-2 years. Market Size: The market for healthcare partnerships in China is estimated to be worth $10 billion annually.
Government Healthcare Reforms: The Chinese government is implementing healthcare reforms to improve access to healthcare and reduce costs. These reforms could create new opportunities for JRSIS Health Care Corporation, such as increased government funding for hospitals and new regulations that favor private healthcare providers. Timeline: Ongoing. Market Size: The Chinese government is investing billions of dollars in healthcare infrastructure and services.
Telemedicine Integration: JRSIS Health Care Corporation can integrate telemedicine into its operations to reach more patients and improve its efficiency. This could involve offering online consultations, remote monitoring, and virtual care services. The market for telemedicine in China is growing rapidly, driven by increasing internet penetration and the rising demand for convenient healthcare services. Timeline: 1-2 years. Market Size: The Chinese telemedicine market is projected to reach $20 billion by 2025.

JRSIS Health Care Corporation operates Jiarun Hospital, a 950-bed facility in Harbin, China.
The company offers a wide range of medical services, including pediatrics, dermatology, and traditional Chinese medicine.
The company's profit margin is -47.0%, indicating significant financial challenges.
The company's P/E ratio is -0.49, reflecting its negative earnings.
The company's gross margin is 15.3%.

JRSS提供哪些产品和服务？

Operates Jiarun Hospital, a 950-bed medical facility.
Provides pediatric medical services.
Offers dermatological treatments.
Specializes in ear, nose, and throat care.
Practices traditional Chinese medicine.
Provides ophthalmology services.
Offers internal medicine and dentistry.
Performs general surgery and rehabilitation science.

JRSS如何赚钱？

Generates revenue through patient fees for medical services.
Receives payments from insurance companies and government healthcare programs.
Offers a range of medical specialties to attract a diverse patient base.

Residents of Harbin and the Heilongjiang Province seeking medical care.
Patients requiring specialized medical treatments.
Individuals covered by health insurance plans.

Established presence in the Heilongjiang Province.
950-bed hospital capacity provides a significant infrastructure base.
Broad range of medical services offers a comprehensive healthcare solution.

什么因素可能推动JRSS股价上涨？

Ongoing: Potential government healthcare reforms in China could benefit private healthcare providers.
Upcoming: Expansion of medical services at Jiarun Hospital could attract more patients.
Ongoing: Increased demand for healthcare services in the Heilongjiang Province due to an aging population.

JRSS的主要风险是什么？

Ongoing: Negative profit margin (-47.0%) raises concerns about financial sustainability.
Potential: Intense competition from other hospitals and clinics in the region.
Potential: Regulatory changes impacting healthcare operations in China.
Potential: Economic downturn affecting patient affordability and demand for services.
Ongoing: OTC listing and limited financial disclosure increase investment risk.

JRSS的核心优势是什么？

Comprehensive range of medical services.
Relatively large hospital capacity (950 beds).
Established presence in Harbin, Heilongjiang Province.

JRSS的劣势是什么？

Negative profit margin (-47.0%).
Limited geographic diversification.
OTC listing may limit access to capital.

JRSS有哪些机遇？

Expanding medical services to meet growing demand.
Leveraging government healthcare reforms.
Forming strategic partnerships with other healthcare providers.

JRSS面临哪些威胁？

Intense competition from other hospitals and clinics.
Regulatory changes impacting healthcare operations.
Economic downturn affecting patient affordability.

JRSS的竞争对手是谁？

Better Health Acquisition Corp. — Focuses on acquiring healthcare businesses. — (BIEI)
CAF Environmental Services, Inc. — Provides environmental services, potentially impacting healthcare facilities. — (CAFS)
Dynatronics Corporation — Manufactures and distributes rehabilitation equipment. — (DYNT)
ITNS Holding Corporation — Unknown business model. — (ITNS)
KJ Financial, Inc. — Unknown business model. — (KJFI)

Key Metrics

MoonshotScore: 35/100

Company Profile

CEO: Linhai Zhu
Headquarters: Yongzhou, CN
Employees: 36
Founded: 2016

AI Insight

AI analysis pending for JRSS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does JRSIS Health Care Corporation do?

JRSIS Health Care Corporation operates Jiarun Hospital in Harbin, China, providing a range of medical services to the local population. The hospital offers services in various medical fields, including pediatrics, dermatology, traditional Chinese medicine, and general surgery. With 950 beds, Jiarun Hospital aims to provide comprehensive healthcare solutions to residents of the Heilongjiang Province. The company generates revenue through patient fees and payments from insurance companies and government healthcare programs. The company faces challenges related to profitability and operates in a competitive healthcare market.

What do analysts say about JRSS stock?

There is currently no available analyst coverage or consensus on JRSIS Health Care Corporation (JRSS) due to its OTC listing and limited financial disclosure. Key valuation metrics, such as price targets and earnings estimates, are not available. Investors should conduct their own thorough research and due diligence before considering an investment in JRSS. The company's negative profit margin and limited liquidity raise concerns about its financial performance and investment risk. Potential investors should carefully consider the risks and opportunities associated with investing in an OTC-listed company with limited information.

What are the main risks for JRSS?

The main risks for JRSIS Health Care Corporation include its negative profit margin, which raises concerns about its financial sustainability. The company's OTC listing and limited financial disclosure increase investment risk due to lack of transparency. Intense competition from other hospitals and clinics in the region could impact patient volume and revenue. Regulatory changes impacting healthcare operations in China could also pose a risk. An economic downturn could affect patient affordability and demand for services. Investors should carefully consider these risks before investing in JRSS.